LONDON - The imminent entry of several companies, including big pharma, small biotech and generic participants, into the global biosimilars space will propel the market towards exponential growth. Already, Indian groups such as Dr. Reddys Laboratories, Biocon and Reliance Life Sciences are making a concerted effort to enter the European market. Although these companies have not yet penetrated the European market due to the stringent regulatory pathway, new product launches are expected in the mid-term. Biosimilar markets in countries such as the U.S. and Japan are also expected to grow exponentially with more clarity on the regulatory pathway.
New research from Frost & Sullivans (http://www.lifesciences.frost.com) Analysis of the Global Biosimilars Market finds the market earned revenue of about $1.2 billion in 2013 and estimates this to reach approximately $24 billion in 2019. Untapped U.S. markets with a strong biosimilars pipeline as well as markets in Asia-Pacific and Latin America with a low cost of manufacturing will afford key growth opportunities.
On one hand, the market is powering ahead regarding the strength of participants global expansion strategies, and, on the other, it is still beset by traditional patent-infringement issues, said Frost & Sullivan Healthcare Senior Research Analyst K. Srinivas Sashidhar. Moreover, the strategies adopted by innovator companies need to be taken into account. For instance, Johnson & Johnson has extended the European patent life of its innovator drug Remicade until February 2015, thereby delaying the launch of Hospiras biosimilar monoclonal antibody (mAb) Inflectra and Celltrions biosimilar mAb Remsima. To further reduce the time to market, companies should also explore opportunities in mergers and acquisitions and alliances with companies having expertise in biosimilars manufacturing and development like Tevas alliance with Cephalon and Lupin Pharmaceuticals alliance with Neuclone.
In addition to mAbs, follitropins, interferons and low molecular weight heparins are likely to emerge in the long run, added Sashidhar. However, some companies may focus on specific therapeutic classes depending on their capabilities and strategic fit.
For more information on this analysis, please email Anna Zanchi, Corporate Communications, at firstname.lastname@example.org Analysis of the Global Biosimilars Market is part of the Life Sciences Growth Partnership Service program. Frost & Sullivans related studies include: Analysis of European Biosimilars Market, Specialty Physicians Discuss their Opinions of the United States Biosimilars Market, Opportunity Analysis for Biosimilars - South Korea and Strategic Analysis of Indian Biosimilar Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact us: Start the discussion
Contact Anna Zanchi Corporate Communications Europe
P: +39.02.4851 6133
To unsubscribe, please email email@example.com
Anna Zanchi PhD
Marketing & Communications Executive
Italian Office Administrator
Frost & Sullivan
Direct: +39.02.4851 6133
Fax: +39.02.4802 7054
"We Accelerate Growth"
Join us at Frost & Sullivan's premier client event, Growth, Innovation and Leadership: A Frost & Sullivan Global Congress on Corporate Growth.
Please consider the environment before printing this email. Thank you. Frost & Sullivan Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com. This email, its content and any files transmitted with it are intended solely for the addressee(s) and may be legally privileged and/or confidential. If you are not the intended recipient please delete and contact the sender by return. Messages sent via this medium may be subject to delays, non-delivery and unauthorized alteration. This email has been prepared using information believed by the author to be reliable and accurate, but Frost & Sullivan makes no warranty as to accuracy or completeness. In particular, Frost & Sullivan does not accept responsibility for changes made to this email after it was sent. Any opinions or recommendations expressed herein are solely those of the author. They may be subject to change without notice.